MELANOMA · White paper
Melanoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About melanoma — and why its trials are hard
Melanoma is an aggressive skin cancer arising from melanocytes, strongly linked to UV exposure, lighter skin, and genetic factors; BRAF mutations occur in roughly 50% of cutaneous melanomas and about 5-10% of cases are hereditary. Its treatment has been revolutionized by immune checkpoint inhibitors and targeted therapy. Ipilimumab (anti-CTLA-4) was the first agent to improve overall survival, followed by the PD-1 inhibitors pembrolizumab and nivolumab, the nivolumab-plus-ipilimumab combination, and the LAG-3/PD-1 combination nivolumab-relatlimab (Opdualag). For BRAF V600-mutant disease, BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) paired with MEK inhibitors (trametinib, cobimetinib, binimetinib) deliver high response rates, and tumor-infiltrating lymphocyte therapy (lifileucel) added a cell-based option. Pivotal endpoints include overall survival, progression-free survival, objective response rate, and duration of response, assessed by RECIST v1.1 with blinded review. Failed candidates, including selumetinib, oblimersen, and various combinations, plus historically limited vaccine and cytokine approaches, illustrate the difficulty of overcoming melanoma's molecular heterogeneity and combination toxicities.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Ipilimumab (Yervoy) | 2011 | Unresectable or metastatic melanoma | MDX010-20 | Overall survival (OS) | Median OS 10.1 vs 6.4 months vs gp100 vaccine control; first agent to improve OS |
| Pembrolizumab (Keytruda) | 2014 | Unresectable or metastatic melanoma (also adjuvant Stage III) | KEYNOTE-006 | Overall survival and PFS | 12-month OS 74.1% vs 58.2% with ipilimumab; median PFS 5.5 vs 2.8 months |
| Nivolumab (Opdivo) | 2014 | Unresectable or metastatic melanoma | CheckMate-037 / CheckMate-066 | Objective response rate and OS | ORR 32% in ipilimumab-refractory patients; improved survival vs chemotherapy |
| Dabrafenib + trametinib (Tafinlar + Mekinist) | 2013 (combination approved 2014) | BRAF V600E/K-mutant unresectable or metastatic melanoma | BREAK-3 (dabrafenib); COMBI-d/COMBI-v (combination) | Progression-free survival and ORR | Dabrafenib median PFS 5.1 vs 2.7 months, ORR 52%; combination improves PFS/OS over BRAF monotherapy |
| Nivolumab + relatlimab (Opdualag) | 2022 | Unresectable or metastatic melanoma | RELATIVITY-047 | Progression-free survival (PFS) | Median PFS 10.1 vs 4.6 months vs nivolumab alone; first LAG-3-blocking combination |
| Lifileucel (Amtagvi) | 2024 | Unresectable/metastatic melanoma after prior therapy (TIL cell therapy) | C-144-01 | Objective response rate (ORR) | ORR 36.4% with median DoR 8.4 months; first FDA-approved cell therapy for melanoma |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in melanoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Selumetinib (MEK inhibitor) — NCT01974752 (with dacarbazine) | Failed to improve progression-free survival vs dacarbazine alone | MEK inhibition alone insufficient, especially paired with a weak backbone agent |
| Oblimersen (Genasense) — AGENDA (with dacarbazine) | Failed to achieve the primary endpoint of improved overall survival | Bcl-2 targeting alone could not overcome melanoma's complex survival mechanisms |
| Trametinib + ipilimumab — NCT01320085 | Trial terminated early | High liver toxicity from combining MEK inhibition with checkpoint blockade (overlapping toxicities) |
Choosing the right endpoint
Primary endpoints that matter in melanoma trials
- Overall Survival (OS) — Definitive endpoint; requires long follow-up and can be confounded by subsequent therapies (RPSFT/IPCW adjustments used)
- Progression-Free Survival (PFS) — Surrogate for OS; needs centralized blinded imaging, complicated by immunotherapy pseudo-progression
- Objective Response Rate (ORR) — Proportion with complete or partial response by RECIST v1.1; pivotal for accelerated approvals such as lifileucel
- Duration of Response (DoR) — Length of sustained tumor response; key for durable-benefit immunotherapies and cell therapy
- Recurrence-Free Survival (RFS) — Primary endpoint in adjuvant resected melanoma trials (e.g., pembrolizumab KEYNOTE-054)
How iNGENū runs melanoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Melanoma clinical trials — FAQs
Why is BRAF status important in melanoma trials?
How did immunotherapy change melanoma outcomes?
Why have many melanoma combination trials failed?
Ready to discuss your melanoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal